Ayala Pharmaceuticals Inc (ADXS)
0.625
+0.09
(+17.81%)
USD |
OTCM |
May 08, 15:54
Ayala Pharmaceuticals Research and Development Expense (Quarterly): 5.41M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.41M |
| September 30, 2023 | 5.683M |
| June 30, 2023 | 5.723M |
| December 31, 2022 | 7.569M |
| September 30, 2022 | 7.199M |
| June 30, 2022 | 5.58M |
| March 31, 2022 | 7.503M |
| December 31, 2021 | 7.527M |
| September 30, 2021 | 7.368M |
| June 30, 2021 | 8.121M |
| Date | Value |
|---|---|
| March 31, 2021 | 6.925M |
| December 31, 2020 | 6.79M |
| September 30, 2020 | 5.421M |
| June 30, 2020 | 5.067M |
| March 31, 2020 | 5.128M |
| December 31, 2019 | 3.861M |
| September 30, 2019 | 4.372M |
| June 30, 2019 | 3.439M |
| March 31, 2019 | 2.752M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.439M
Minimum
Jun 2019
8.121M
Maximum
Jun 2021
6.038M
Average
5.703M
Median
Research and Development Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |
| Oragenics Inc | 11.04M |